Synergistic autophagy effect of miR-212-3p in zoledronic acid-treated in vitro and orthotopic in vivo models and in patient-derived osteosarcoma cells

Ju Yeon Oh, Eun Ho Kim, Yeon Joo Lee, Sei Sai, Sun Ha Lim, Jang Woo Park, Hye Kyung Chung, Joon Kim, Guillaume Vares, Akihisa Takahashi, Youn Kyoung Jeong, Mi Sook Kim, Chang Bae Kong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Osteosarcoma (OS) originates from osteoid bone tissues and is prone to metastasis, resulting in a high mortality rate. Although several treatments are available for OS, an effective cure does not exist for most patients with advanced OS. Zoledronic acid (ZOL) is a third-generation bisphosphonate that inhibits osteoclast-mediated bone resorption and has shown efficacy in treating bone metastases in patients with various types of solid tumors. Here, we sought to clarify the mechanisms through which ZOL inhibits OS cell proliferation. ZOL treatment inhibited OS cell proliferation, viability, and colony formation. Autophagy inhibition by RNA interference against Beclin-1 or ATG5 inhibited ZOL-induced OS cell death. ZOL induced autophagy by repressing the protein kinase B/mammalian target of rapamycin/p70S6 kinase pathway and extracellular signal-regulated kinase signaling-dependent autophagy in OS cell lines and patient-derived OS cells. Microarrays of miRNA showed that ZOL increased the levels of miR-212-3p, which is known to play an important role in autophagy, in OS in vitro and in vivo systems. Collectively, our data provided mechanistic insight into how increased miR-212-3p through ZOL treatment induces autophagy synergistically in OS cells, providing a preclinical rationale for conducting a broad-scale clinical evaluation of ZOL + miR-212-3p in treating OS.

Original languageEnglish
Article number1812
JournalCancers
Volume11
Issue number11
DOIs
Publication statusPublished - 2019 Nov

Fingerprint

zoledronic acid
Autophagy
Osteosarcoma
In Vitro Techniques
Cell Proliferation
Neoplasm Metastasis

Keywords

  • Autophagy
  • MiR-212
  • Osteosarcoma
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Synergistic autophagy effect of miR-212-3p in zoledronic acid-treated in vitro and orthotopic in vivo models and in patient-derived osteosarcoma cells. / Oh, Ju Yeon; Kim, Eun Ho; Lee, Yeon Joo; Sai, Sei; Lim, Sun Ha; Park, Jang Woo; Chung, Hye Kyung; Kim, Joon; Vares, Guillaume; Takahashi, Akihisa; Jeong, Youn Kyoung; Kim, Mi Sook; Kong, Chang Bae.

In: Cancers, Vol. 11, No. 11, 1812, 11.2019.

Research output: Contribution to journalArticle

Oh, JY, Kim, EH, Lee, YJ, Sai, S, Lim, SH, Park, JW, Chung, HK, Kim, J, Vares, G, Takahashi, A, Jeong, YK, Kim, MS & Kong, CB 2019, 'Synergistic autophagy effect of miR-212-3p in zoledronic acid-treated in vitro and orthotopic in vivo models and in patient-derived osteosarcoma cells', Cancers, vol. 11, no. 11, 1812. https://doi.org/10.3390/cancers11111812
Oh, Ju Yeon ; Kim, Eun Ho ; Lee, Yeon Joo ; Sai, Sei ; Lim, Sun Ha ; Park, Jang Woo ; Chung, Hye Kyung ; Kim, Joon ; Vares, Guillaume ; Takahashi, Akihisa ; Jeong, Youn Kyoung ; Kim, Mi Sook ; Kong, Chang Bae. / Synergistic autophagy effect of miR-212-3p in zoledronic acid-treated in vitro and orthotopic in vivo models and in patient-derived osteosarcoma cells. In: Cancers. 2019 ; Vol. 11, No. 11.
@article{640b293a03324b248f50fad4dc5ceb4e,
title = "Synergistic autophagy effect of miR-212-3p in zoledronic acid-treated in vitro and orthotopic in vivo models and in patient-derived osteosarcoma cells",
abstract = "Osteosarcoma (OS) originates from osteoid bone tissues and is prone to metastasis, resulting in a high mortality rate. Although several treatments are available for OS, an effective cure does not exist for most patients with advanced OS. Zoledronic acid (ZOL) is a third-generation bisphosphonate that inhibits osteoclast-mediated bone resorption and has shown efficacy in treating bone metastases in patients with various types of solid tumors. Here, we sought to clarify the mechanisms through which ZOL inhibits OS cell proliferation. ZOL treatment inhibited OS cell proliferation, viability, and colony formation. Autophagy inhibition by RNA interference against Beclin-1 or ATG5 inhibited ZOL-induced OS cell death. ZOL induced autophagy by repressing the protein kinase B/mammalian target of rapamycin/p70S6 kinase pathway and extracellular signal-regulated kinase signaling-dependent autophagy in OS cell lines and patient-derived OS cells. Microarrays of miRNA showed that ZOL increased the levels of miR-212-3p, which is known to play an important role in autophagy, in OS in vitro and in vivo systems. Collectively, our data provided mechanistic insight into how increased miR-212-3p through ZOL treatment induces autophagy synergistically in OS cells, providing a preclinical rationale for conducting a broad-scale clinical evaluation of ZOL + miR-212-3p in treating OS.",
keywords = "Autophagy, MiR-212, Osteosarcoma, Zoledronic acid",
author = "Oh, {Ju Yeon} and Kim, {Eun Ho} and Lee, {Yeon Joo} and Sei Sai and Lim, {Sun Ha} and Park, {Jang Woo} and Chung, {Hye Kyung} and Joon Kim and Guillaume Vares and Akihisa Takahashi and Jeong, {Youn Kyoung} and Kim, {Mi Sook} and Kong, {Chang Bae}",
year = "2019",
month = "11",
doi = "10.3390/cancers11111812",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Synergistic autophagy effect of miR-212-3p in zoledronic acid-treated in vitro and orthotopic in vivo models and in patient-derived osteosarcoma cells

AU - Oh, Ju Yeon

AU - Kim, Eun Ho

AU - Lee, Yeon Joo

AU - Sai, Sei

AU - Lim, Sun Ha

AU - Park, Jang Woo

AU - Chung, Hye Kyung

AU - Kim, Joon

AU - Vares, Guillaume

AU - Takahashi, Akihisa

AU - Jeong, Youn Kyoung

AU - Kim, Mi Sook

AU - Kong, Chang Bae

PY - 2019/11

Y1 - 2019/11

N2 - Osteosarcoma (OS) originates from osteoid bone tissues and is prone to metastasis, resulting in a high mortality rate. Although several treatments are available for OS, an effective cure does not exist for most patients with advanced OS. Zoledronic acid (ZOL) is a third-generation bisphosphonate that inhibits osteoclast-mediated bone resorption and has shown efficacy in treating bone metastases in patients with various types of solid tumors. Here, we sought to clarify the mechanisms through which ZOL inhibits OS cell proliferation. ZOL treatment inhibited OS cell proliferation, viability, and colony formation. Autophagy inhibition by RNA interference against Beclin-1 or ATG5 inhibited ZOL-induced OS cell death. ZOL induced autophagy by repressing the protein kinase B/mammalian target of rapamycin/p70S6 kinase pathway and extracellular signal-regulated kinase signaling-dependent autophagy in OS cell lines and patient-derived OS cells. Microarrays of miRNA showed that ZOL increased the levels of miR-212-3p, which is known to play an important role in autophagy, in OS in vitro and in vivo systems. Collectively, our data provided mechanistic insight into how increased miR-212-3p through ZOL treatment induces autophagy synergistically in OS cells, providing a preclinical rationale for conducting a broad-scale clinical evaluation of ZOL + miR-212-3p in treating OS.

AB - Osteosarcoma (OS) originates from osteoid bone tissues and is prone to metastasis, resulting in a high mortality rate. Although several treatments are available for OS, an effective cure does not exist for most patients with advanced OS. Zoledronic acid (ZOL) is a third-generation bisphosphonate that inhibits osteoclast-mediated bone resorption and has shown efficacy in treating bone metastases in patients with various types of solid tumors. Here, we sought to clarify the mechanisms through which ZOL inhibits OS cell proliferation. ZOL treatment inhibited OS cell proliferation, viability, and colony formation. Autophagy inhibition by RNA interference against Beclin-1 or ATG5 inhibited ZOL-induced OS cell death. ZOL induced autophagy by repressing the protein kinase B/mammalian target of rapamycin/p70S6 kinase pathway and extracellular signal-regulated kinase signaling-dependent autophagy in OS cell lines and patient-derived OS cells. Microarrays of miRNA showed that ZOL increased the levels of miR-212-3p, which is known to play an important role in autophagy, in OS in vitro and in vivo systems. Collectively, our data provided mechanistic insight into how increased miR-212-3p through ZOL treatment induces autophagy synergistically in OS cells, providing a preclinical rationale for conducting a broad-scale clinical evaluation of ZOL + miR-212-3p in treating OS.

KW - Autophagy

KW - MiR-212

KW - Osteosarcoma

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=85075192007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075192007&partnerID=8YFLogxK

U2 - 10.3390/cancers11111812

DO - 10.3390/cancers11111812

M3 - Article

AN - SCOPUS:85075192007

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 11

M1 - 1812

ER -